Search Results - "Vinay, S Postel"

Challenges of phase 1 clinical trials evaluating immune checkpoint-targeted antibodies by Postel-Vinay, S., Aspeslagh, S., Lanoy, E., Robert, C., Soria, J.-C., Marabelle, A.

“…Immunostimulatory monoclonal antibodies (imAbs) targeting immune checkpoint molecules are revolutionizing oncology not only regarding cancer therapeutics and…”
Get full text

Immunotherapy phase I trials in patients Older than 70 years with advanced solid tumours by Herin, H., Aspeslagh, S., Castanon, E., Dyevre, V., Marabelle, A., Varga, A., Postel Vinay, S., Michot, J.M., Ribrag, V., Gazzah, A., Bahleda, R., Mir, O., Massard, C., Hollebecque, A., Soria, J.C., Baldini, C.

“…The development of immune checkpoint blocker development brings new hope in older patients (OPs) because of clinical efficacy and low toxicity. Clinical…”
Get full text

A high-throughput screen identifies PARP1/2 inhibitors as a potential therapy for ERCC1-deficient non-small cell lung cancer by Postel-Vinay, S, Bajrami, I, Friboulet, L, Elliott, R, Fontebasso, Y, Dorvault, N, Olaussen, K A, André, F, Soria, J-C, Lord, C J, Ashworth, A

“…Excision repair cross-complementation group 1 (ERCC1) is a DNA repair enzyme that is frequently defective in non-small cell lung cancer (NSCLC). Although low…”
Get full text

Clinical benefit in Phase-I trials of novel molecularly targeted agents: does dose matter? by Postel-Vinay, S, Arkenau, H-T, Olmos, D, Ang, J, Barriuso, J, Ashley, S, Banerji, U, De-Bono, J, Judson, I, Kaye, S

“…Phase-I trials traditionally involve dose-escalation to determine the maximal tolerated dose (MTD). With conventional chemotherapy, efficacy is generally…”
Get full text

Predictors of chemotherapy efficacy in non-small-cell lung cancer: a challenging landscape by Olaussen, K.A., Postel-Vinay, S.

“…Conventional cytotoxic chemotherapy (CCC) is the backbone of non-small-cell lung cancer (NSCLC) treatment since decades and still represents a key element of…”
Get full text

Immune-related adverse events with immune checkpoint blockade: a comprehensive review by Michot, J.M, Bigenwald, C, Champiat, S, Collins, M, Carbonnel, F, Postel-Vinay, S, Berdelou, A, Varga, A, Bahleda, R, Hollebecque, A, Massard, C, Fuerea, A, Ribrag, V, Gazzah, A, Armand, J.P, Amellal, N, Angevin, E, Noel, N, Boutros, C, Mateus, C, Robert, C, Soria, J.C, Marabelle, A, Lambotte, O

“…Abstract Cancer immunotherapy is coming of age; it has prompted a paradigm shift in oncology, in which therapeutic agents are used to target immune cells…”
Get full text

Phase II study of an optimized 5-fluorouracil-oxaliplatin strategy (OPTIMOX2) with celecoxib in metastatic colorectal cancer: a GERCOR study by André, T., Tournigand, C., Mineur, L., Fellague-Chebra, R., Flesch, M., Mabro, M., Hebbar, M., Postel Vinay, S., Bidard, F.C., Louvet, C., de Gramont, A.

“…Background: Oxaliplatin stop and go in combination with leucovorin and 5-fluorouracil has been successfully used in a previous study (OPTIMOX1) in metastatic…”
Get full text

Phase I–II trial designs: how early should efficacy guide the dose recommendation process? by Paoletti, X., Postel-Vinay, S.

Get full text

Epigenetic modifiers as new immunomodulatory therapies in solid tumours by Aspeslagh, S., Morel, D., Soria, J.-C., Postel-Vinay, S.

“…Immune therapies have revolutionized cancer treatment over the last few years by allowing improvements in overall survival. However, the majority of patients…”
Get full text

Long lasting major response to pembrolizumab in a thoracic malignant rhabdoid-like SMARCA4-deficient tumor by Henon, C., Blay, J.-Y., Massard, C., Mir, O., Bahleda, R., Dumont, S., Postel-Vinay, S., Adam, J., Soria, J.-C., Le Cesne, A.

Get full text

Targeting cell cycle dependencies represent a novel therapeutic approach for selected sarcoma subgroups by Adam, J., Postel-Vinay, S.

Get full text

Targeting chromatin defects in selected solid tumors based on oncogene addiction, synthetic lethality and epigenetic antagonism by Morel, D., Almouzni, G., Soria, J.-C., Postel-Vinay, S.

“…Although the role of epigenetic abnormalities has been studied for several years in cancer genesis and development, epigenetic-targeting drugs have…”
Get full text

Oncology phase I trial design and conduct: time for a change - MDICT Guidelines 2022 by Araujo, D., Greystoke, A., Bates, S., Bayle, A., Calvo, E., Castelo-Branco, L., de Bono, J., Drilon, A., Garralda, E., Ivy, P., Kholmanskikh, O., Melero, I., Pentheroudakis, G., Petrie, J., Plummer, R., Ponce, S., Postel-Vinay, S., Siu, L., Spreafico, A., Stathis, A., Steeghs, N., Yap, C., Yap, T.A., Ratain, M., Seymour, L.

“…In 2021, the Food and Drug Administration Oncology Center of Excellence announced Project Optimus focusing on dose optimization for oncology drugs. The…”
Get full text

Professional burnout in European young oncologists: results of the European Society for Medical Oncology (ESMO) Young Oncologists Committee Burnout Survey by Banerjee, S., Califano, R., Corral, J., de Azambuja, E., De Mattos-Arruda, L., Guarneri, V., Hutka, M., Jordan, K., Martinelli, E., Mountzios, G., Ozturk, M.A., Petrova, M., Postel-Vinay, S., Preusser, M., Qvortrup, C., Volkov, M.N.M., Tabernero, J., Olmos, D., Strijbos, M.H.

“…Burnout in health care professionals could have serious negative consequences on quality of patient care, professional satisfaction and personal life. Our aim…”
Get full text

Phase I study of the checkpoint kinase 1 inhibitor GDC-0575 in combination with gemcitabine in patients with refractory solid tumors by Italiano, A., Infante, J.R., Shapiro, G.I., Moore, K.N., LoRusso, P.M., Hamilton, E., Cousin, S., Toulmonde, M., Postel-Vinay, S., Tolaney, S., Blackwood, E.M., Mahrus, S., Peale, F.V., Lu, X., Moein, A., Epler, J., DuPree, K., Tagen, M., Murray, E.R., Schutzman, J.L., Lauchle, J.O., Hollebecque, A., Soria, J.-C.

“…Checkpoint kinase 1 (Chk1) inhibition following chemotherapy-elicited DNA damage overrides cell cycle arrest and induces mitotic catastrophe and cell death…”
Get full text

Phase I trials in oncology: a new era has started by Postel-Vinay, S., Soria, J.-C.

Get full text

Safety profile of epigenetic therapies in early phase trials: Do epidrugs deserve specific drug development processes? by Leroy, L, Satar, T, Baldini, C, Martin-Romano, P, Hollebecque, A, Michot, J-M, Ribrag, V, Massard, C, Paoletti, X, Postel Vinay, S

Get full text

Initial results from a phase I/IIa trial evaluating BMS-986158, an inhibitor of the bromodomain and extra-terminal (BET) proteins, in patients (pts) with advanced cancer by Hilton, J, Cristea, M C, Voskoboynik, M, Postel-Vinay, S, Edenfield, W, Gavai, A, Wee, S, Srivastava, N, Klippel, A, Jackson, D, Apfel, A, Chasalow, S D, Williams, D, Donovan, M, Fischer, B, Khaldoyanidi, S, Diamond, J R

Get full text

Molecular alterations and matched treatment in older patients: Results from the MOSCATO 01 trial by Vuagnat, P., Baldini, C., Verlingue, L., Martin Romano, P., Varga, A., Hollebecque, A., Postel-Vinay, S., Gazzah, A., Bahleda, R., Marabelle, A., Ribrag, V., Champiat, S., Michot, J.-M., Soria, J.-C., Massard, C.

Get full text

Applicability of the lung immune prognostic index (LIPI) to metastatic triple negative breast cancer (mTNBC) patients treated with immune checkpoint targeted monoclonal antibodies (ICT mAbs) by Vozy, A., Simonaggio, A., Auclin, E., Mezquita, L., Baldini, C., Martin-Romano, P., Pistilli, B., Gazzah, A., Bahleda, R., Ribrag, V., Postel-Vinay, S., Champiat, S., Soria, J.-C., André, F., Massard, C., Besse, B., Delaloge, S., Varga, A.

Get full text